NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 ...
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...
HONOLULU (KHON2) — Hawaii continues its battle with coconut rhinoceros beetles moving from infested to non-infested areas throughout the state. Download the free KHON2 app for iOS or Android to stay ...
A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC). This is an ASCO Meeting Abstract from the ...
KAUNAKAKAI (KHON2) — Molokaʻi residents are sounding the alarm, calling for urgent action to prevent the invasive coconut rhinoceros beetle from reaching their shores. Potted plant shipment delivers ...
After five of the 11 nominees for the Civilian Review Board were nearly unanimously voted down, community members have mixed feelings regarding the process of the board’s establishment. Last January, ...
Corbus Pharmaceuticals initiates combination cohort of CRB-701 study for solid tumors, focusing on HNSCC and cervical cancer. Data update expected this year. Corbus Pharmaceuticals Holdings, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback